Sigal, the company’s executive vice president, chief scientific officer and president, research & development, oversees the company’s research, discovery, and development functions.
Huet was promoted to executive vice president and chief financial officer, will also oversee the areas of strategy and productivity in addition to finance.
“This group will chart the future for Bristol-Myers Squibb,” said Cornelius. “Our transformation over the past 15 months has been swift and seamless, and we will continue to move forward as a company purely focused on helping patients prevail against serious disease.”
In other changes announced by Cornelius,
Anthony Hooper has been named president, Americas, Beatrice Cazala has been named president, global commercialization, and president, Europe, John Celentano has been named president, emerging markets and Asia-Pacific, Carlo De Notaristefani has been named president, technical operations and global support functions and Giovanni Caforio has been named senior vice president, global and US Oncology.